Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: August 2, 2024
Reporting Period: Immediate event reporting for transactions closed or entered into on August 2, 2024.
Business Context: The Company is an emerging growth company listed on the Nasdaq Capital Market. This filing details two concurrent capital raising transactions: a warrant inducement agreement to facilitate the exercise of existing warrants and a registered direct offering with a concurrent private placement of new warrants.
Key Financial Metrics and Transaction Details
Transaction 1: Warrant Inducement Agreement
- Existing Warrant Exercise: Holders agreed to exercise warrants for up to 1,041,667 shares of Common Stock.
- Exercise Price: Reduced from $1.64 to $1.25 per share.
- Expected Gross Proceeds: Approximately $1.3 million.
- New Warrants Issued: 1,302,082 new warrants (125% of exercised shares) at an exercise price of $1.50 per share.
Transaction 2: Registered Direct Offering and Concurrent Private Placement
- Shares Issued: 360,000 shares of Common Stock in a registered direct offering.
- Private Warrants Issued: 450,000 warrants (125% of shares) at an exercise price of $1.50 per share.
- Expected Gross Proceeds: Approximately $450,000.
Advisory Fees and Compensation
- Financial Advisor: WallachBeth Capital LLC.
- Cash Fee: 8.0% of aggregate gross proceeds from both transactions.
- Warrant Compensation: Issuance of warrants to purchase 49,862 shares (3.0% of total new warrant shares) at $1.50 per share.
Liquidity and Use of Proceeds
- Total Expected Gross Proceeds: Approximately $1.75 million ($1.3M + $0.45M).
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Agreements
Warrant Terms and Conditions
- Exercise Period: New and Private Warrants are exercisable commencing on the "Stockholder Approval Date" and expire on the fifth anniversary of that date.
- Stockholder Approval: Required for the issuance of shares upon exercise of the new warrants. The Company must hold a special meeting within 90 days of the closing date to seek approval.
- Cashless Exercise: If a registration statement is not effective after six months, holders may elect cashless exercise.
- Ownership Cap: Holders cannot exercise if it results in beneficial ownership exceeding 4.99% (or 9.99% upon election) of outstanding shares.
Lock-Up and Market Stand-Off
- Company Lock-Up: No issuance of Common Stock or equivalents for 45 days post-closing; no Variable Rate Transactions for 12 months (ATM offerings restricted for 6 months).
- Insider Lock-Up: Officers and directors are restricted from selling securities for 60 days post-closing.
Support Agreements
- Stockholders holding over 16% of outstanding shares have agreed to vote in favor of the warrant exercise proposal and any adjournments to secure approval.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- The Company expects the transactions to close on or about August 5, 2024.
- Management intends to use commercially reasonable efforts to have resale registration statements declared effective within 45 days.
- The Company will solicit proxies for the special stockholder meeting to approve the warrant exercises.
Risks and Contingencies
- Stockholder Approval Risk: The new warrants cannot be exercised until stockholder approval is obtained. If approval is not granted at the first meeting, the Company must call meetings every six months until approval is obtained or warrants expire.
- Registration Risk: If the resale registration statement is not effective within six months, holders may be forced to use cashless exercise, reducing potential equity value.
- Dilution: The issuance of new shares and warrants will result in dilution to existing shareholders.
- Financial Advisor Rights: WallachBeth Capital LLC has a right of first refusal for six months on future equity/debt offerings and is entitled to fees on future transactions with parties they introduce.
Investor Verification Checklist
- Stockholder Approval Status: Verify the date and outcome of the special stockholder meeting required to enable warrant exercises.
- Registration Statement Effectiveness: Confirm the filing and effectiveness of the Form S-1 resale registration statements for the new warrant shares.
- Actual Proceeds: Monitor the final closing to confirm the actual gross proceeds received versus the estimated $1.75 million.
- Warrant Exercise Activity: Track whether holders of the existing warrants actually exercise their options at the reduced price of $1.25.
- Insider Trading Activity: Monitor for any insider sales during the 60-day lock-up period expiration.